Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Proteomic and genetic approaches identify Syk as an AML target.

  PMID 19800574 · PMC2803063 · Cancer cell · 2009 · 8 claims · 8 setups

  Full-text index only

  EGFR inhibitors (e.g., gefitinib) induce AML differentiation through a non-EGFR, off-target mechanism

  hl-60 aml molm-14 luciferase-labeled phospho-tyrosine kinome-wide secondary

• Discovery and identification of potential biomarkers of papillary thyroid carcinoma.

  PMID 19785722 · PMC2761863 · Molecular cancer · 2009 · 8 claims · 7 setups

  Full-text index only

  A 3-peak (m/z 9190, 6631, 8697 Da) SVM classification model discriminates PTC from non-cancer controls with high sensitivity and specificity

  serum hplc-purified trypsin-digested crude seldi-tof-ms solid-phase maldi-tof-ms

• Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues.

  PMID 18416831 · PMC2377273 · BMC cancer · 2008 · 6 claims · 4 setups

  Full-text index only

  Three protein spots were significantly altered in abundance between metastase-positive and metastase-negative breast cancer patient groups

  excised formalin-fixed log-normalized two-dimensional liquid immunohistochemistry

• Diagnostic proteomics: serum proteomic patterns for the detection of early stage cancers.

  PMID 15258335 · PMC3851082 · Disease markers · 2003 · 8 claims · 8 setups

  Full-text index only

  Proteomic pattern analysis of serum mass spectra, without identifying the underlying proteins, can distinguish cancer patients from healthy controls with high sensitivity and specificity.

  serum frozen ig-depleted clinical seldi-tof maldi lc-ms

• Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome.

  PMID 18849548 · PMC4260454 · Experimental biology and medicine (Maywood, N.J.) · 2008 · 6 claims · 6 setups

  Full-text index only

  50 μM HU treatment of SS RBC membranes causes statistically significant changes in a discrete set of membrane proteins, distinct from HbF induction.

  sickle rbc excised 2d-dige tandem immunoblot